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University, Ramat Aviv, IsraelAbstractRecent Infectious Diseases Society of America guidelines for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections
recommend maintaining vancomycin trough concentrations of 15–20 mg/L for serious infections. We conducted a systematic review and
meta-analysis of all studies assessing the impact of low (<15 mg/L) vs. high (15 mg/L) vancomycin trough level on the efﬁcacy of MRSA
infections treatment. Four prospective and 12 retrospective studies were included (2003 participants). No signiﬁcant difference was
demonstrated between low and high vancomycin trough level for the outcome of all-cause mortality (odds ratio (OR) 1.07, 95%
conﬁdence interval (CI) 0.78–1.46, I2 = 28%). In studies evaluating mainly MRSA pneumonia, there was signiﬁcantly higher mortality with
low vancomycin level (OR 1.78, 95% CI 1.11–2.84). No signiﬁcant difference was demonstrated in treatment failure rates (OR 1.25, 95%
CI 0.88–1.78, I2 = 51%). However, excluding one outlier study from the analysis, treatment failure became signiﬁcantly higher in patients
with low vancomycin trough level (OR 1.46, 95% CI 1.12–1.91, I2 = 16%). Microbiologic failure rates were signiﬁcantly higher in patients
with low vancomycin levels (OR 1.56, 95% CI 1.08–2.26, I2 = 0%). Nephrotoxicity was signiﬁcantly higher with vancomycin levels of
15 mg/L. However, no cases of irreversible renal damage were reported. Current data on the effectiveness of higher vancomycin
trough levels in the treatment of MRSA infections are limited to few prospective and mainly retrospective studies. Our ﬁndings support
the current recommendations for maintaining vancomycin trough levels of 15 mg/L in the treatment of severe MRSA infections,
although no difference in all-cause mortality was observed.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: noptabi@yahoo.comIntroductionMethicillin-resistant Staphylococcus aureus (MRSA) infections are
associated with signiﬁcant mortality, morbidity and healthcare
costs. Vancomycin remains an important antibiotic for the
treatment of invasive MRSA infections. This is the anti-MRSA
drug with the highest cumulative clinical experience for theClinical Microbiology and Infection © 2015 European Society of Ctreatment of a variety of invasive clinical syndromes, including
bacteremia, endocarditis, pneumonia and osteomyelitis. Its ef-
ﬁcacy, however, has come into question because of its slow
bactericidal activity, the emergence of resistant strains and
possible ‘MIC creep’ among susceptible strains [1,2].
Vancomycin is inferior to β-lactams for treatment of
methicillin-susceptible S. aureus bacteremia and infective
endocarditis [3–5]. Tissue penetration is highly variable and
depends on the degree of inﬂammation. In particular, pene-
tration is limited for bone, lung epithelial lining ﬂuid and cere-
brospinal ﬂuid [6–8].
Trough vancomycin concentrations are the recommended
method to guide vancomycin dosing. Trough concentrations areClin Microbiol Infect 2015; 21: 665–673
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.04.003
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(AUC) to minimum inhibitory concentration (MIC), which in
some studies best predicted efﬁcacy of vancomycin [9]. Recent
Infectious Diseases Society of America (IDSA) guidelines for the
treatment of MRSA infections recommend aiming at vancomycin
trough concentrations of 15–20 mg/L for serious infections,
such as bacteremia, bacterial meningitis, infective endocarditis,
osteomyelitis, pneumonia and severe skin and soft tissue in-
fections. The IDSA recommend the use of higher vancomycin
doses than approved by the US Food and Drug Administration
because of vancomycin treatment failures in patients with MRSA
infection along with in vitro susceptibility and pharmacodynamics
data suggesting that maintaining a AUC/MIC >400 may be
associated with improved clinical outcome [10,11]. However, a
recent meta-analysis of 15 studies demonstrated a signiﬁcantly
higher rates of nephrotoxicity with higher vancomycin troughs
levels (15 mg/L) relative to lower troughs of <15 mg/L [12].
In light of these uncertainties, we conducted a systematic
review and meta-analysis of all studies assessing the impact of
vancomycin trough concentration monitoring and levels on the
efﬁcacy of MRSA infection treatment.MethodsInclusion criteria and outcomes
We included all randomized controlled clinical trials, prospec-
tive cohort studies and retrospective cohort studies comparing
different vancomycin trough concentration in the treatment of
adults (18 years and older) with MRSA infections and sepsis
including bacteremia, pneumonia, endocarditis, skin and soft
tissue, osteomyelitis, catheter-related and other (urinary tract
infection, cerebrospinal ﬂuid infection, septic arthritis). We
excluded studies that did not report all-cause mortality, clinical
efﬁcacy or microbiologic efﬁcacy. Because a recent meta-
analysis [12] investigated the correlation between vancomycin
through levels and nephrotoxicity, we did not include studies
reporting only nephrotoxicity without efﬁcacy outcomes. The
primary outcome was 30 day all-cause mortality. If 30-day
mortality was unavailable, we extracted in-hospital mortality.
Secondary outcomes were as follows: treatment failure,
microbiologic failure, infection-related mortality, nephrotoxi-
city [13–16], fever duration, length of hospitalization and
adverse events. Treatment failure was deﬁned as any combi-
nation of clinical or radiologic nonimprovement or worsening;
need for antibiotic modiﬁcation; microbiologic failure at 7
days or death. Nephrotoxicity was deﬁned as increase in serum
creatinine of 0.5 mg/dL or more or 50% of baseline for 2
consecutive days during the period from initiation of vanco-
mycin therapy to 72 hours after completion of therapy. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectspeciﬁc adverse events we looked for were ototoxicity [17],
hematologic [18–21], central nervous system [22,23], derma-
tologic [24–27] and cardiovascular [28,29].
Search strategy
We searched the PubMed (1948 to April 2014) and Cochrane
Central Register of Controlled Trials (Central) databases
(http://www.cochrane-handbook.org). The search terms we
used included ‘monitoring’ OR ‘surveillance’ AND ‘vancomy-
cin.’ Unpublished trials were sought in references of all selected
studies, relevant conference proceedings (Antimicrobial Agents
and Chemotherapy (ICAAC), European Society of Clinical
Microbiology and Infectious Diseases (ECCMID), Infectious
Disease Conferences (IDSA)), trial registries and ongoing trial
databases. In addition, we contacted the ﬁrst or corresponding
author of each included study for additional information, and
researchers active in the ﬁeld for information on unpublished
studies. No language or date restrictions were imposed. The
last search was done in December 2014.
Study selection and data extraction
Two authors (TS and DY) independently applied the inclusion
criteria to all identiﬁed and retrieved articles. In addition, the
two authors independently performed data extraction using a
data extraction form.
Assessment of risk of bias in included studies
Two review authors (TS and DY) independently assessed the
risks of bias in studies fulﬁlling the review inclusion criteria.
Because only cohort studies were available for inclusion,
quality assessment was performed according to the Newcastle-
Ottawa Scale (http://www.cochrane-handbook.org). We
assessed the following items (Supplementary Table 1): (a) se-
lection, including representativeness of the exposed cohort,
selection of the nonexposed cohort and ascertainment of
exposure; (b) comparability of cohorts; and (c) outcome,
including assessment of outcome (independent blind assessment/
record linkage/self report/no description), length of follow-up
for outcomes to occur and adequacy of follow-up of cohorts.
Statistical analysis
Odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
calculated for individual studies. Heterogeneity in the results of
the trials was assessed using the chi-square test for heterogeneity
and the I2 measure of inconsistency [30]. If no signiﬁcant het-
erogeneity was found, meta-analysis was done using the Mantel-
Haenszel ﬁxed-effects model (RevMan) [31]. If signiﬁcant het-
erogeneity was found (I2 > 50%), the meta-analysis was done using
the Mantel-Haenszel random-effects model. ORs >1 favour high
vancomycin trough levels for all comparisons. We plannedious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 665–673
CMI Steinmetz et al. Efﬁcacy of high vs. low vancomycin concentration 667subgroup analyses by type of infection and by Newcastle-Ottawa
Scale grading. A funnel plot was used to assess small-study effects.ResultsWe retrieved 53 publications for full-text inspection, of which
37 were excluded (Fig. 1).FIG. 1. Study ﬂow diagram.
Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologySixteen studies assessing the inﬂuence of vancomycin
trough level on different efﬁcacy variables were included. No
randomized controlled trials were identiﬁed. Four of the
studies were prospective cohort studies [11,32–34] and 12
were retrospective cohort studies [35–44] (Choi et al.,
personal communication, 2011). The studies were conducted
between 2006 and 2013, and encompassed 2003 participants.
The mean or median patient age ranged between 52 and 82and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 665–673
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was examined in four studies [11,32,36,38] and the initial
trough value in 13 studies [11,34,35,37–40,43–46] (Choi
et al., personal communication, 2011; Casapao et al., personal
communication, 2013). Two studies reported vancomycin
MIC levels [38,39] and 4 studies reported AUC or AUC/MIC
ratio [32,33,35,46]. Albur et al. [38] reported a mean MIC
level of 0.72 ± 0.12 mg/L, and Arshad et al. [39] reported a
mean MIC level of 0.53 ± 0.23 mg/L. All studies except four
[34,44] (Choi et al., personal communication, 2011; Casapao
et al., personal communication, 2013) reported mortality,
seven [11,32,35,36,40,42,43] reported in hospital mortality
and ﬁve [35–37,42,45] reported 30-day all-cause mortality.
For the outcomes of fever duration, adverse effects and
length of hospitalization, we did not perform a pooled anal-
ysis as a result of the scarcity of data. We planned to search
the studies for multivariate-adjusted OR, but only one
study reported adjusted OR (Casapao et al., personal
communication, 2013). Study characteristics are detailed in
Table 1.
Risk of bias in included studies
The 16 cohort studies included in the review scored between 6
and 8 (out of a maximum of 8 points) on the Newcastle-Ottawa
Scale adapted for our review (Supplementary Table 2).TABLE 1. Study characteristics
Study Design Type of infection
No. of
patients
Age (mean
median ± S
Kullar 2012 [37] Retrospective Bacteremia 261 High level: 53
low level: 5
Kullar 2010 [44] Retrospective Bacteremia 320 71.6 ± 14.2 m
Albur 2011 [38] Retrospective Bacteremia 38 NS
Arshad 2012 [39] Retrospective Bacteremia 200 NS
Casapao 2013 Retrospective Bacteremia 128 NS
Chan 2011 [40] Retrospective Bacteremia,
pneumonia
113 53.9 ± 16.6 (
Choi 2011 Retrospective Bacteremia 73 NS
Chung 2011 [32] Prospective Pneumonia 141 High level: 66
low level: 6
(median)
Forstner 2013 [41] Retrospective Bacteremia 124 64.5 (median)
Hermsen 2010 [36] Retrospective Pneumonia, mixed 55 High level: 60
low level: 5
Holmes 2013 [33] Prospective Pneumonia, mixed 182 NS
Jeffers 2006 [35] Retrospective Bacteremia,;
pneumonia
102 59.4 ± 15.3 (
Mizokami 2013 [42] Retrospective Bacteremia,
pneumonia
94 82 (median)
Zelenitsky 2012 [43] Retrospective Bacteremia,
pneumonia,
mixed
35 61.9 ± 15.2 (
Wunderink 2012 [34] Prospective Bacteremia,
pneumonia
138 61.6 ± 17.7 (
Hidayat 2006 [11] Prospective Bacteremia,
pneumonia,
mixed
95 High level: 72
low level: 7
(mean)
High level, vancomycin trough level 15 mg/L; low level, vancomycin trough level <15 mg/L, m
central nervous system infection, catheter-related infection; NS, not speciﬁed.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectPrimary outcome
All-cause mortality. Twelve cohort studies addressed our pri-
mary outcome of all-cause mortality, three prospective studies
[11,32,33] and nine retrospective studies [35–43] (1344 pa-
tients). There was no signiﬁcant difference in mortality rates
between low (<15 mg/L) and high (15 mg/L) vancomycin
trough level (OR 1.07, 95% CI 0.78–1.46, without signiﬁcant
heterogeneity, I2 = 28%). In the prospective studies, the OR
was 1.42, with 95% CI 0.84–2.42, without signiﬁcant hetero-
geneity (I2 = 0%) (Fig. 2). The funnel plot for 30-day all-cause
mortality showed no small-studies effect (Supplementary
Fig. 1).
Sensitivity analysis based on the Newcastle-Ottawa Scale
revealed no signiﬁcant difference in mortality rates between
low and high vancomycin trough level in studies with a total
score of 7–8 [11,32,33,35,36,38,40–44] (OR 1.25, 95% CI
0.89–1.78), or in studies with total score of 6 [37,39] and
below (OR 0.49, 95% CI 0.23–1.07) (Supplementary Fig. 2).
There was a trend, however, for higher mortality with low
vancomycin levels in studies with higher score.
We performed an analysis of mortality subcategorized by
type of infection. Signiﬁcantly higher mortality in the low van-
comycin level group was demonstrated among patients with
pneumonia (OR 1.78, 95% CI 1.11–2.84, ﬁve studies), but not
among patients with bacteremia.or
D)
Vancomycin
trough level
(initial and/or
average)
Vancomycin trough
level (mg/L)
AUC (0–24)
(μg/h/mL)
;
2 (median)
Initial High level: 15.8;
low level: 12.3
(median)
NS
edian Initial NS NS
Initial and average Initial: 10.64;
Average: 14.01
NS
Initial NS NS
Initial NS NS
median) Initial High level: 21.0 ± 5.3;
low level: 8.8 ± 3.4
NS
Initial NS NS
.9 ± 11.4;
0.3 ± 12.5
Average High level: 16.2 ± 2.1;
low level: 7.8 ± 2.4
(mean)
+
Initial NS NS
;
9 (median)
Average High level: 16.9;
low level: 11.4
(median)
NS
Initial NS 416.2 (median)
median) Initial High level: 20.4 ± 3.2;
low level: 9.4 ± 3.2
High level: 418 ± 152;
low level: 318 ± 111
Initial NS NS
median) Initial NS +
mean) Initial 12.3 (median) NS
.4 ± 14.8;
2.7 ± 17.4
Initial and average NS NS
ixed infection–urinary tract infection, endocarditis, osteomyelitis, skin and soft tissue,
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 665–673
FIG. 2. All-cause mortality. An odds ratio of >1 favours high vancomycin level.
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three prospective [11,32,34] and the rest retrospective
[35–37,39–41,44] (Casapao et al., personal communication,
2013) (1323 patients). There was no signiﬁcant difference in
treatment failure rates between low and high vancomycin
trough level (OR 1.25, 95% CI 0.88–1.78, with signiﬁcant
heterogeneity, I2 = 51%). When we excluded the study of
Hermsen et al. [36], which was an outlier, from the analysis,
treatment failure rates were signiﬁcantly lower in patients with
high vancomycin trough level (OR 1.46, 95% CI 1.12–1.91)
without signiﬁcant heterogeneity (I2 = 16%) (Fig. 3). The
rationale for excluding this study was that Hermsen et al. re-
ported a signiﬁcantly higher median Acute Physiology and
Chronic Health Evaluation II (APACHE II) score, higher sepsis
rates and nonsigniﬁcantly more cardiac arrest and mechanical
ventilation in the high vancomycin group.
Microbiologic failure. Six studies reported microbiologic failure,
two of them prospective [32,33] and four retrospective [37,39]
(Choi et al., personal communication, 2011; Casapao et al.,
personal communication, 2013) (889 patients). Microbiologic
failure was deﬁned as persistent bacteremia 7 days while
receiving vancomycin therapy or at end of treatment. Micro-
biologic failure was signiﬁcantly higher in patients with lowClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyvancomycin trough level (OR 1.56, 95% CI 1.08–2.26, without
signiﬁcant heterogeneity, I2 = 0%) (Fig. 4).
Nephrotoxicity. Five studies reported nephrotoxicity
[11,36,39,44] (Choi et al., personal communication, 2011), four
retrospective [35,39,44] (Choi et al., personal communication,
2011) (702 patients). All studies deﬁned nephrotoxicity as in-
crease in serum creatinine of 0.5 mg/dL or more or 50% of
baseline for two consecutive days. Nephrotoxicity was signiﬁ-
cantly lower in patients with low vancomycin trough level (OR
0.46, 95% CI 0.29–0.73, without signiﬁcant heterogeneity,
I2 = 40%) (Supplementary Fig. 3). All studies reported no
irreversible damage to kidney function; one [11] reported that
patients’ serum creatinine level returned to normal before
discharge, and three [35,39] (Choi et al., personal communi-
cation, 2011) reported that no patient required renal replace-
ment therapy.DiscussionMonitoring vancomycin levels has been demonstrated to
improve clinical efﬁcacy and decrease nephrotoxicity in patients
with Gram-positive infections [45,46]. However, the targetand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 665–673
FIG. 3. Treatment failure. An odds ratio of >1 favours high vancomycin level.
670 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIlevel is not well deﬁned. Current recommendations are on
maintaining a level of 15–20 mg/L for serious MRSA infections.
In this meta-analysis, we found no statistically signiﬁcant
difference in mortality rates between low (<15 mg/L) and highFIG. 4. Microbiologic failure. An odds ratio of >1 favours high vancomycin
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(15 mg/L) vancomycin trough (OR 1.07, 95% CI 0.78–1.46).
Analyzing studies including mostly patients with pneumonia
separately demonstrated signiﬁcantly lower mortality in the
high-vancomycin group. Most of the effect was driven by onelevel.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 665–673
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due to pneumonia [43]. Treatment failure was not signiﬁcantly
different between the two groups (OR 1.25, 95% CI 0.88–1.78,
with signiﬁcant heterogeneity). However, excluding one outlier
study [36] from the analysis, the results became signiﬁcant (OR
1.50, 95% CI 1.19–1.89), and heterogeneity was eliminated.
Microbiologic failure was signiﬁcantly higher in the low-level
group (OR 1.56, 95% CI 1.08–2.26, number needed to treat
14). Several studies reported an association between microbi-
ologic failure and poor clinical outcomes in patients with
S. aureus bacteremia. Chong et al. [47] reported longer hospital
stay and higher relapse rate and attributable mortality with
persistent bacteremia beyond 7 days. Ok et al. [48] reported
signiﬁcantly higher 30-day mortality in patients with persistent
MRSA bacteremia. Kullar et al. [49], in a recent review of the
literature, concluded that persistent MRSA bacteremia beyond
7 days is associated with poor clinical outcomes.
Higher vancomycin troughs levels (15 mg/L) were associ-
ated with higher rates of nephrotoxicity (OR 0.46, 95% CI
0.29–0.73, 5 studies, number needed to harm 10). No cases of
irreversible kidney damage were reported. The risk of
vancomycin-associated nephrotoxicity was well demonstrated
in a recent meta-analysis [12]. The meta-analysis included 15
studies and showed that higher levels (15 mg/L) were asso-
ciated with increased odds of nephrotoxicity. This nephrotox-
icity was reversible in the majority of cases, with short-term
dialysis required only in 3% of nephrotoxic episodes, and no
patient needed long-term dialysis. In all patients who required
dialysis, other concomitant nephrotoxins were documented.
Several limitations of our review should be noted. Most
included studies were small retrospective cohort studies. These
studies may be subject to selection bias with sicker patients
included in the high-vancomycin group. This may be either due
to lower creatinine clearance in severely septic patients, causing
higher vancomycin levels, or to the administration of higher
vancomycin doses to septic patients. Most included studies did
not report signiﬁcant differences in baseline characteristics of
patients who received low-vancomycin therapy compared to
high-level therapy. However, in the study of Hermsen et al.
[36], the differences were signiﬁcant and may have inﬂuenced
the results. In addition, it should be stated that our results are
based on univariate, unadjusted comparisons. Another potential
source for bias is that most of the studies [11,33–35,37–44]
(Choi et al., personal communication, 2011; Casapao et al.,
2013), reported the initial trough value, but four [11,32,36,38]
reported the average trough value over the duration of therapy.
Data on efﬁcacy of vancomycin maintained at levels between
10 and 15 mg/L were too scarce to compile. We cannot rule
out the possibility that these levels will achieve similar clinical
results with fewer adverse effects. We could not evaluate theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyefﬁcacy of different vancomycin levels in the treatment of deep
infections (e.g. osteomyelitis, endocarditis), necessitating good
penetration of antibiotics and thus perhaps higher drug levels.
Although the studies are fairly recent, we were not able to
extract data on the distribution of MIC values, reported in only
two studies.
Overall, our results of lower microbiologic failure and
possibly lower treatment failure in the high-vancomycin group
support IDSA recommendations for maintaining trough levels
of >15 mg/L in the treatment of severe MRSA infections
[45,50]. As noted in the guidelines, higher vancomycin levels
may be considered to improve tissue penetration in deep in-
fections. It should be noted, however, that no difference in all-
cause mortality was demonstrated in our analysis. Large pro-
spective studies evaluating the efﬁcacy and safety of vancomycin
levels in the range of 10 to 20 mg/L are needed. In addition, a
randomized controlled trial aiming for trough levels of 10–12
to 15 mg/L vs. 15–20 should be considered.Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
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